Farletuzumab-MMAE is an antibody-drug conjugate (ADC) composed of humanized anti-human folate receptor-alpha (FRα) and the cytotoxic agent monomethyl auristatin (MMAE) via a MC-Vc linker. It has a potent antitumor activity.